Suppr超能文献

Sch 39304在粒细胞减少和非粒细胞减少兔体内的药代动力学及组织穿透情况

Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits.

作者信息

Lee J W, Lin C, Loebenberg D, Rubin M, Pizzo P A, Walsh T J

机构信息

Infectious Disease Section, National Cancer Institute, Bethesda, Maryland 20892.

出版信息

Antimicrob Agents Chemother. 1989 Nov;33(11):1932-5. doi: 10.1128/AAC.33.11.1932.

Abstract

We studied the plasma pharmacokinetics and tissue penetration of Sch 39304 (SCH), a new antifungal triazole, in granulocytopenic [G(+)] and nongranulocytopenic [G(-)] rabbits. Five female New Zealand White G(-) rabbits were given a single oral dose of 2 mg of SCH per kg of body weight. Levels in plasma, determined by gas-liquid chromatography-electron capture, were obtained for 6 days. This procedure was repeated 2 weeks later with the same rabbits, which were induced and maintained G(+) with cytosine arabinoside. There were no significant differences between the pharmacokinetic parameters of G(+) and G(-) rabbits. Among all animals studied, the maximum concentration of the drug in plasma was 1.4 +/- 0.11 micrograms/ml at 4 +/- 0.5 h, the half-life was 25 +/- 1.4 h, the volume of distribution at steady state was 3.8 +/- 0.3 liters, and the area under the concentration-time curve was 44 +/- 3.4 micrograms.h/ml. SCH was detectable in plasma up to day 6. Levels of SCH in tissue were studied at steady state in six G(+) and six G(-) rabbits receiving 2 mg of the drug orally per kg per day for experimental disseminated candidiasis. Tissue SCH levels equalled or exceeded those in plasma (at steady state) at all sites examined, and these ratios were similar in both G(+) and G(-) rabbits. Thus, plasma pharmacokinetics of orally administered SCH were similar for G(+) and G(-) rabbits, and SCH achieved high levels of penetration into multiple tissues, including the liver and the central nervous system.

摘要

我们研究了新型抗真菌三唑类药物Sch 39304(SCH)在粒细胞缺乏[G(+)]和非粒细胞缺乏[G(-)]兔体内的血浆药代动力学及组织穿透情况。五只雌性新西兰白兔(G(-))每千克体重单次口服2毫克SCH。采用气液色谱-电子捕获法测定血浆水平,持续6天。两周后对同组兔子重复此操作,并用阿糖胞苷诱导并维持其粒细胞缺乏状态(G(+))。G(+)和G(-)兔的药代动力学参数无显著差异。在所有研究动物中,药物在血浆中的最大浓度在4±0.5小时时为1.4±0.11微克/毫升,半衰期为25±1.4小时,稳态分布容积为3.8±0.3升,浓度-时间曲线下面积为44±3.4微克·小时/毫升。直至第6天血浆中均可检测到SCH。在患有实验性播散性念珠菌病的6只G(+)和6只G(-)兔中,在稳态下研究了组织中的SCH水平。在所检查的所有部位,组织中的SCH水平均等于或超过血浆中的水平(稳态时),且这些比值在G(+)和G(-)兔中相似。因此,口服SCH后,G(+)和G(-)兔的血浆药代动力学相似,且SCH在包括肝脏和中枢神经系统在内的多个组织中均达到了较高的穿透水平。

相似文献

1
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits.
Antimicrob Agents Chemother. 1989 Nov;33(11):1932-5. doi: 10.1128/AAC.33.11.1932.
2
Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.
Antimicrob Agents Chemother. 1990 Jun;34(6):1281-4. doi: 10.1128/AAC.34.6.1281.
3
Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing.
Antimicrob Agents Chemother. 1992 Dec;36(12):2790-3. doi: 10.1128/AAC.36.12.2790.
4
SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.
Antimicrob Agents Chemother. 1990 Aug;34(8):1560-4. doi: 10.1128/AAC.34.8.1560.
5
Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.
Antimicrob Agents Chemother. 1990 Nov;34(11):2240-5. doi: 10.1128/AAC.34.11.2240.
6
Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts.
Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S307-17. doi: 10.1093/clinids/12.supplement_3.s307.
7
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.
Antimicrob Agents Chemother. 2000 Mar;44(3):727-31. doi: 10.1128/AAC.44.3.727-731.2000.
9
Pharmacokinetics and tissue penetration of fluconazole in rabbits.
Antimicrob Agents Chemother. 1989 Apr;33(4):467-9. doi: 10.1128/AAC.33.4.467.
10
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Antimicrob Agents Chemother. 2001 Dec;45(12):3322-7. doi: 10.1128/AAC.45.12.3322-3327.2001.

引用本文的文献

1
Systemic antifungal agents.
Tex Heart Inst J. 1990;17(3):194-202.
2
Pharmacokinetics and metabolism of genaconazole, a potent antifungal drug, in men.
Antimicrob Agents Chemother. 1996 Jan;40(1):92-6. doi: 10.1128/AAC.40.1.92.
3
Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.
Antimicrob Agents Chemother. 1994 Dec;38(12):2758-62. doi: 10.1128/AAC.38.12.2758.
4
Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.
Antimicrob Agents Chemother. 1990 Jun;34(6):1281-4. doi: 10.1128/AAC.34.6.1281.
5
SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.
Antimicrob Agents Chemother. 1990 Aug;34(8):1560-4. doi: 10.1128/AAC.34.8.1560.
6
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.
Antimicrob Agents Chemother. 1990 Jun;34(6):980-4. doi: 10.1128/AAC.34.6.980.
7
Treatment of murine coccidioidal meningitis with SCH39304.
Antimicrob Agents Chemother. 1990 Apr;34(4):663-4. doi: 10.1128/AAC.34.4.663.
8
Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
Antimicrob Agents Chemother. 1991 Oct;35(10):1985-8. doi: 10.1128/AAC.35.10.1985.
9
Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing.
Antimicrob Agents Chemother. 1992 Dec;36(12):2790-3. doi: 10.1128/AAC.36.12.2790.

本文引用的文献

4
Treatment of systemic fungal infections: recent progress and current problems.
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460-75. doi: 10.1007/BF01962595.
5
Azole antifungal agents: emphasis on new triazoles.
Antimicrob Agents Chemother. 1988 Jan;32(1):1-8. doi: 10.1128/AAC.32.1.1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验